Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Disease Progression × marizomib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ependymoma 1 Disease Progression 1

Interventions

vandetanib 2 Lenalidomide 2 Bortezomib 2 marizomib 1 Tamoxifen 1 Steroids 1 Irinotecan 1 Dexamethasone 1 Carboplatin 1 Calcium Dobesilate 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated

4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡